ライフサイエンスコーパス: die

1 eding grounds, where they mate, lay eggs and die.

2 for sepsis may miss patients who ultimately die.

3 f these critically ill patients subsequently die.

4 sensitive, undergo mitotic catastrophe, and die.

5 fection, whereas others rapidly progress and die.

6 es or autophagosomes and macrophages did not die.

7 % according to histo score (HScore); 9 (43%) died.

8 urvivors to hospital discharge and those who died.

9 8 developed hemolytic uremic syndrome, and 5 died.

10 ian duration, 6 days; range, 0-50), and none died.

11 %) participants developed IRIS and 31 (6.5%) died.

12 n the BD group and 26 in the C-BD group) had died.

13 ile range: 1.04 to 4.29 years), 167 patients died.

14 One child in the study cohort died.

15 ped ACLF, 54 (30%) underwent LT and 35 (19%) died.

16 nd 178 of 468 (38%) in the placebo group had died.

17 ) required liver transplantation and 8 (11%) died.

18 3.0 (IQR 1.2-4.8) years, 613 (41%) patients died.

19 D-19, 77 (21%) were hospitalized, and 9 (2%) died.

20 e study due to an adverse event; no patients died.

21 , 45 (96%) of whom fully recovered and 2 who died.

22 112 experienced disease progression, and 69 died.

23 Thirty-nine of 180 (22%) patients with SD died.

24 re admitted to an intensive care unit, and 2 died.

25 y department, 1 (<1%) was hospitalized; none died.

26 th kidney replacement therapy, and 553 (21%) died.

27 ch, by 30 March 13% were hospitalized and 2% died.

28 remaining persistently elevated in those who died.

29 ne and 1 (<1%) of 387 patients given placebo died.

30 e live birth infants weighed <=500 g and 336 died.

31 728 patients with a known outcome, 193 (27%) died.

32 Nine patients (7 adults and 2 children) died.

33 idly diagnosed tuberculosis in up to 89% who died.

34 76%) patients were hospitalised and 66 (33%) died.

35 children with SAM who survived and those who died.

36 sm; 7 required mechanical ventilation, and 1 died.

37 One patient died.

38 ipants progressed to kidney failure, and 803 died.

39 , 2/23 were still hospitalized, and 4/23 had died.

40 recovered with conservative management and 1 died.

41 en, 2/7 were still hospitalized, and 1/7 had died.

42 vived, whereas all infants with rintSO2 <35% died.

43 alysis (May 7, 2020), 121 (13%) patients had died.

44 follow-up of 16.1 years, 38,178 participants died.

45 reached several millimeters before suddenly dying.

46 y hospitalized patients, have a high risk of dying.

47 Thirteen participants died, 10 with decompensated liver disease pre-LT and thr

48 ntentional chloroquine overdoses, of whom 33 died (11%), and 16 healthy volunteers who took 620 mg ba

49 ubjects (88.9%) were alive and 43 of 389 had died (11.1%); 203 of 389 (52.2%) had completed paired he

50 p to this date, 879 (41%) of these women had died, 1118 (52%) were alive, and 159 (7%) were censored

51 Among 743 NP patients, 64 died, 13 were lost to follow up; therefore, a total of 6

52 Survival of 148 individuals (58 died, 15 dropouts) was well described by an exponentiall

53 Sixteen patients died (18% overall, 24% of hospitalized, 52% of ICU) and

54 p and 3 in the control group), and 4 of them died (2 in each randomized group).

55 The antecedents were (1) awareness of dying, (2) living with life-threatening illness, (3) pos

56 ) had QTc prolongation >500 milliseconds and died 20 months after discontinuing bedaquiline of a caus

57 of AGE inpatient cases had ICU stays and 2% died; 3 deaths were associated with C. difficile and 1 w

58 Three patients died (30%), and 5 (50%) developed acute kidney injury.

59 mitted to an ICU; at 6 months, 188 (73%) had died, 39 (15%) were dependent, and 32 (12%) were functio

60 Six of 143 died (4%) vs 362 of 2095 patients (17%, P < .001).

61 tients had telemetric monitoring, and either died (52) or were discharged (88).

62 9%) patients died in hospital, and 456 (84%) died 6 months after injury.

63 Of 507 febrile adults, 32 died (6.3%) within 28 days of presentation.

64 At 12 months, 19 patients had died (9 in the BD group v 10 in the C-BD group), includi

65 Thirty-three patients (69%) died, 94% for HCC progression.

66 By end of follow-up, 18 patients (31%) died a median 6 days after hospitalization, including 75

67 ents of live cells until the cell eventually dies, a process termed amebic trogocytosis.

68 of 1242 (43.8%) in the usual care group had died (absolute risk difference, -2.85%; 95% CI, -6.75 to

69 load of at least 1000 copies per muL or had died (adjusted prevalence ratio 0.58, 95% CI 0.36-0.94;

70 s with adult congenital heart disease (ACHD) die after the age of 40 years, and heart failure (HF) is

71 16 for patients who were hospitalized or who died after >=1 dose of isoniazid-rifapentine for treatme

72 -p450camfusion showed that the E. coli cells died after five days but a variety of bacteria received

73 matic case fatality risk (the probability of dying after developing symptoms) of COVID-19 in Wuhan wa

74 Strikingly, the proportion of flies dying after M. luteus infection was significantly lower

75 During the 32-y follow-up, 982 participants died and 281 reached 90 y of age.

76 1 (62%) had been discharged alive, 178 (29%) died and 55 (9%) remained hospitalized at censoring.

77 Among all patients, 131 (16%) died and 694 (83%) were discharged (523 [63%] had mild t

78 e model discriminated well between those who died and those who survived (C statistic = 0.84), but th

79 The mFI of patients who survived or died and were readmitted or not were compared.

80 elta(13) C and delta(18) O, respectively) of dying and surviving conifers at eight old-growth forest

81 r-use efficiency increased over time in both dying and surviving trees, with a weaker increase in dyi

82 nge: 1.3 to 5.3 years), 830 (16.4%) patients died, and 1,048 (20.7%) had MACEs.

83 During the study, 4 children died, and 102 children developed severe acute malnutriti

84 ents were intubated, of whom 66 subsequently died, and 166 died without intubation).

85 6-month outcomes, 16 (64%) survived, 7 (28%) died, and 2 (8%) were lost.

86 CRS concurrent with culture-positive sepsis died, and 3 achieved CR.

87 om COVID-19 pneumonia; 36/315 patients (11%) died, and 3/315 patients (1%) remained admitted in the h

88 533 patients (22%) were intubated, 627 (25%) died, and 59 (2%) remained hospitalized.

89 ponse to cisplatin, cells either arrested or died, and the ratio of these outcomes depended on the do

90 mean = 9.9 years, standard deviation = 5.0), died, and underwent a neuropathologic examination to qua

91 teritis daily and more than 2 million people die annually in developing countries due to such patholo

92 at mass lysis occurs when cells are going to die anyway from toxin exposure.

93 cules that select interneurons to survive or die are unknown.

94 Two of his older male siblings died around 2-3 years of age due to pneumonia.

95 Lineage tracing confirmed that germ cells die as clones independent of intercellular bridges, sugg

96 Four patients (6%) died as a result of toxicity.

97 ulation causes those cells near the crack to die, as indicated by live-dead and caspase staining.

98 Patients with diabetes appear to die at a higher frequency during the sub-acute phase.

99 Every year, hundreds of people die at sea because of vessel and airplane accidents.

100 ome coronavirus 2 (SARS-CoV-2) infection who died at a university medical center in Germany.

101 14 patients without pulmonary embolism (52%) died at ICU discharge (odds ratio 0.79 [0.24-3.26]; p =

102 pressible female lethal system where females died at late larval/pupal stages.

103 of 13 356 patients (17.5%) in the H2RB group died at the hospital by day 90 (risk ratio, 1.05 [95% CI

104 of 13 415 patients (18.3%) in the PPI group died at the hospital by day 90 and 2333 of 13 356 patien

105 d, daughters born to older mothers tended to die before reaching ages at which such senescent decreas

106 Four patients died before 4 years of age.

107 IP mutations, we tested if the affected twin died before the unaffected twin, as a direct measurement

108 their 16th birthday, and 11 161 children who died before their 16th birthday, resulting in a final sa

109 se of MSCs were significantly less likely to die but experienced equivalent collapse of the hematopoi

110 s commonly detach from the surface when they die, but some toxic compounds promote cell adhesion.

111 hout the world, approximately 800,000 people die by suicide every year, accounting for 1.5% of all de

112 uired mechanical ventilation, and 77 (20.5%) died by 28 days after diagnosis.

113 h RT alone (15 Gy, single dose), all animals died by 72 days; INP pretreatment resulted in longer-ter

114 One patient died by sudden death in the placebo group.

115 cancer cell lines and the majority of cells died by treatment-induced apoptosis.

116 Because tumor antigens and DNA released by dying cancer cells have the potential to amplify innate

117 age-associated molecular patterns (DAMPs) by dying cancer cells.

118 ase dUTP nick end labelling (TUNEL)-positive dying cells and reduced infarct growth from 12 to 72 h.

119 our work reveals a novel connection between dying cells and stem cells that remain.

120 The number of dying cells increased with 200 mug/g b.w.

121 covery that the metabolite cargo of dead and dying cells ingested through efferocytosis by macrophage

122 hat the biomarker is released passively from dying cells.

123 ears of follow-up, 30,389 (38%) participants died, corresponding to 22 deaths per 1,000 person-years.

124 Since slot-die deposition enables printing enzymes without signific

125 Approximately one third of cancer patients die due to complexities related to cachexia.

126 One patient who received atezolizumab died due to a treatment-related adverse event (haemophag

127 develop ACLF and patients who did vs did not die during hospitalization and within 30 days.

128 vs 94.9%, P < .0001) and were more likely to die during treatment (18.9% vs 2.1%, P < .0001).

129 18% required mechanical ventilation and 21% died during follow-up (compared with 23% and 20%, respec

130 nts survived while all osteosarcoma patients died during follow-up.

131 Thirty patients (39.0%) died during follow-up.

132 admitted to an intensive care unit, and 6.2% died during hospitalization.

133 ad noncardiopulmonary complications and 5.4% died during hospitalization.

134 b group (cause of death unknown; the patient died during sleep).

135 The patients who died during the first 48 hours after venoarterial extrac

136 SD and seven (0.2%) of 4074 matched controls died during the follow-up period (HR 2.78, 95% CI 0.95-8

137 ere readmitted at least once while 22 (7.9%) died during the follow-up period.

138 732(29.87%) of patients died during the follow-up.

139 yoclonus were variable, with one patient who died during the study period and five who were successfu

140 Three patients died during the study, from causes judged unrelated to a

141 Overall, 71 (49%) patients died during the study, most frequently because of diseas

142 rsing homes, we identified all residents who died during the three months prior to measurements.

143 18%) required ventilator support, and 2 (5%) died during their hospital admission.

144 l ventilation, 19% had shock, and 588 (3.1%) died during their hospitalization.

145 y of regions and species sampled, trees that died during water shortages were less resilient to previ

146 s rate [ER] = 9.2%; 95% CI: 4.3%, 14.3%) and DIE (ER = 3.9%; 95% CI: 1.1%, 6.8%) for lag days 0-3.

147 uffer from opiate use disorder, and over 100 die every day from opioid overdoses.

148 h (uDCD) refers to donation from persons who die following an unexpected and unsuccessfully resuscita

149 Among them, four (27%) died following splenectomy performed for spontaneous spl

150 ts tested positive after LT, and one patient died for COVID on POD 30.

151 anges in the peripheral lung of patients who die from Covid-19.

152 ht serve to identify patients more likely to die from the SARS-CoV-2 infection, regardless of age.

153 Each year, 3.4 million people die from waterborne diseases worldwide.

154 gs obtained during autopsy from patients who died from acute respiratory distress syndrome (ARDS) sec

155 he lives of many more mammals than have ever died from allergy, so justifying the positive role of Ig

156 One (2%) patient died from cardiac arrest, possibly treatment related.

157 to week 24, one patient in the placebo group died from cardiac failure and two had serious infections

158 cells in brain sections from 34 children who died from CM or other causes.

159 gs obtained during autopsy from patients who died from Covid-19 and compared them with 7 lungs obtain

160 In patients who died from Covid-19-associated or influenza-associated re

161 In the UC cohort, 639 patients died from CRC (0.55 per 1000 person-years), compared wit

162 o present three case reports of patients who died from EVALI to illustrate the clinical characteristi

163 c lung cancer, one patient assigned riluzole died from ischaemic heart disease and coronary artery th

164 ve treatment; one patient assigned amiloride died from metastatic lung cancer, one patient assigned r

165 ssive disease, and one patient (2%) each had died from therapy-related or other causes.

166 sociated with greater risk of developing and dying from an SPC, compared with the general population.

167 gher for 18 of the 30 FPC types, and risk of dying from any SPCs was statistically significantly high

168 r (HR 1.16, 95% CI 1.08-1.24, p < 0.001) and dying from cancer (HR 1.27, 95% CI 1.15-1.41, p < 0.001)

169 Black/African Americans are contracting and dying from COVID-19 disproportionately.

170 n of minority individuals diagnosed with and dying from COVID-19.

171 s advanced CRC, and are at increased risk of dying from CRC, although these excess risks have decline

172 D (HR 1.39, 95% CI 1.34-1.43, p < 0.001) and dying from CVD (HR 1.45, 95% CI 1.29-1.62, p < 0.001), a

173 at an early stage and can reduce the risk of dying from lung cancer.

174 x vivo PrPSc derived from the brains of mice dying from M1000 prion disease.

175 Septic patients who died had early, profound, and sustained suppression of i

176 ironment, especially macrophages in clearing dying hepatocytes.

177 e system, which tags intruding pathogens and dying host cells for clearance.

178 est discrimination (C statistic = 0.82; 1.5% died if no danger signs, 10% if 1 danger sign, and 33% i

179 12 made a partial recovery, and one patient died; (iii) ischaemic strokes (n = 8) associated with a

180 The majority of children with NPC die in adolescence.

181 n protein, Drp1 (dynamin-related protein 1), die in embryogenesis and show an accumulation of cluster

182 stay (odds ratio, 4.4; 95% CI, 3.0-6.4), and die in hospital (odds ratio, 6.4; 95% CI, 2.8-14.0) (p <

183 ural people to manage serious illness and to die in place.

184 inase that dictates whether cells survive or die in response to the cytokine tumor necrosis factor (T

185 an acute inpatient hospital and subsequently die in that setting; or if they survive to discharge fro

186 d]) length of stay, and were more likely to die in the ICU (12.3% vs 7.5%) and in-hospital (20.8% vs

187 ring the index admission were more likely to die in the skilled nursing facility; more likely to be r

188 Ten (14%) of 69 patients died in complete remission from sepsis (two [3%]), cardi

189 over the 10-year period; 428 (79%) patients died in hospital, and 456 (84%) died 6 months after inju

190 10 698 (11.1%) patients died in hospital.

191 owed TdP, 5 (45%) were stillborn, and 1 (9%) died in infancy.

192 h severe COVID-19 who had been discharged or died in Jin Yin-tan hospital and Wuhan union hospital be

193 after surgery, 4.1% and 2.3% of patients had died in the HES and saline groups, respectively (differe

194 were also significantly more likely to have died in the hospital.

195 dible interval, 178,100-231,000) more people died in these countries than would have had the pandemic

196 s, across 613 U.S. hospitals, 12,388 (18.6%) died in-hospital.

197 The odds of dying in a hospice facility (odds ratio, 1.79 [1.75-1.82

198 emergent adverse events occurred; 5 patients died, including 3 after transplant.

199 ian follow-up of 13 years, 2128 participants died, including 488 of cardiovascular causes.

200 Overall, 637 (5%) patients died, including 552 (20%) patients with severe TBI.

201 death events or broke up when their founders died, irrespective of pack size.

202 with pulmonary thromboembolism), one of whom died; (iv) peripheral neurological disorders (n = 8), se

203 total of 1263 out of 13 885 (9.1%) patients died (median follow-up: 30 months).

204 ed (3 in the intensive care unit) and 15 had died (mortality, 26%).

205 re suspended and who were never transplanted died, most often from cardiothoracic causes.

206 atory neurotransmitters, and as Gad1-/- mice die neonatally of severe cleft palate, it has not been p

207 help to regulate brain function by removing dying neurons, pruning non-functional synapses, and prod

208 microglia did not effectively engulf injured/dying neurons.

209 hese strands of DNA extruded by activated or dying neutrophils, decorated with various protein mediat

210 p and two participants in the control group) died; none of the six deaths in the intervention group w

211 or every individual in the United States who died of a firearm injury in 2017, three survived, living

212 During follow-up, 3883 patients died of any cause, and of these, 2131 deaths were the re

213 We report an infant who died of autoinflammation due to a homozygous missense mu

214 performed an autopsy on a single patient who died of COVID-19 after open repair of an aortic dissecti

215 sis (range, 8.9-13.7 months), and 2 patients died of disease.

216 849 of the 7,529,481 cancer patients studied died of heart disease.

217 well, 1 was alive with metastases, and 6 had died of metastatic disease (including 2 patients who dec

218 Forty-five pneumonectomy patients (18%) died of nononcologic causes 1-5 years after surgery; pne

219 through 2014, a total of 8,354 participants died of pancreatic cancer.

220 were alive and disease-free, eight (16%) had died of progressive disease, and one patient (2%) each h

221 ectively, and two-thirds of MDS/AML patients died of pulmonary fibrosis and/or hepatopulmonary syndro

222 dy included 70 lung lobes of 14 patients who died of reverse-transcription polymerase chain reaction-

223 Persons who rapidly died of severe COVID-19 illness may not have had SARS-Co

224 atients, 9 (21%) were alive and 34 (79%) had died of systemic metastasis.

225 Patient 2, whose sister and mother had died of the disease, proceeded to transplantation at age

226 All patients died of their cancer within 6 months after the onset of

227 of poorer states, from their higher risk of dying of COVID-19.

228 tential woody bioenergy feedstock after tree die-off has not been evaluated due to the complexities o

229 Governmental responses to tree die-off have often focused on incentivizing biomass ener

230 croscopy, the metabarcoding data indicated a die-off of larger metazoans during the first week of stu

231 biomass generated by the unprecedented tree die-off that occurred in California following a 4-year d

232 mprove forecasts of forest and agroecosystem die-off.

233 Doing so can reduce the number of people who die on the waitlist by over 500 every year.

234 zone" (i.e., high-risk patients who had not died on follow-up) from 46% to 35% and decreased the HVP

235 The patient died on the fifth day.

236 thin 3 months, 27.8% were transplanted, 4.3% died on the WL, and 4.7% were delisted for other reasons

237 me was the proportion of adolescents who had died or had a viral load of at least 1000 copies per muL

238 us infections; no guselkumab-treated patient died or had serious infections.

239 s in the higher-threshold group, 423 (50.1%) died or survived with neurodevelopmental impairment, as

240 Forty-two cats survived to discharge and 6 died or were euthanized due to a possible cardiac cause.

241 No patients died or were lost to follow-up during the study.

242 tracellular nucleotides that are released by dying or infected cells.

243 cutive patients, 70 patients were intubated, died, or discharged within 24 hours after presentation a

244 ovid-19, excluding those who were intubated, died, or discharged within 24 hours after presentation t

245 Most packs either died out in whole-pack death events or broke up when the

246 eople in quartiles 3 and 4 for plasma sTNFR1 died over 4-year follow-up.

247 (Gopherus agassizii) that either survived or died over a period of two decades.

248 wal of life-sustaining care in an imminently dying patient.

249 Wishes from dying patients, family members, and clinicians were elic

250 sed with severity and, for case patients who died, peaked on the day of death.

251 Most mice with both mutations died perinatally.

252 Eleven infants died postoperatively.

253 out 5.6 million adolescents alive today will die prematurely from a smoking-related illness.

254 Adults with repaired tetralogy of Fallot die prematurely from ventricular tachycardia (VT) and su

255 Nevertheless, p53(KQ/-) mice died prematurely due to anemia and hematopoiesis failure

256 Wbp11 homozygous null embryos die prior to E8.5, indicating that Wbp11 is essential fo

257 all those infected with SARS-CoV-2 who will die ranges from 20% (95% CrI 16%-26%) in Switzerland to

258 Nrf2(-/-)Atg7 (Delta/Delta) mice died rapidly due to small intestine damage, which was no

259 onventional balloon angioplasty participants died (risk ratio, 0.48; 95% CI: 0.04, 5.10).

260 nonfeeding adults mate in swarms and females die shortly after oviposition.

261 e less likely to develop disease symptoms or die, show less severe symptoms, and shed less infectious

262 azon-wide, on average trees are as likely to die standing as they are broken or uprooted-modes of dea

263 al Cx43, and reduced gap junctions, and they died suddenly at 2 to 4 weeks of age.

264 es of CD39(+)CD8(+) T cells and exhausted or dying T cells.

265 ted lymphoma patients experience relapse and die, targeting B-cell lymphomas with a NMT inhibitor pot

266 o be hospitalized, enter intensive care, and die than women.

267 17 (17%) of 99 in the non-randomised cohort died; the median baseline CD4 count for participants who

268 an center outcome rates were 72.6% LT, 18.2% died/too sick, and 6.1% SS.

269 d surviving trees, with a weaker increase in dying trees at five of the eight sites.

270 mpared with surviving trees, lower growth of dying trees was detected at least one decade before mort

271 the phagocytic marker phosphatidylserine on dying tumour cells.

272 Fischer exact tests to compare patients who died versus those still living.

273 dian baseline CD4 count for participants who died was 11 cells per muL.

274 support) within 21 days, where patients who died were assigned -1 day.

275 in Washington, D.C.), and 78.6% of those who died were born during 1945-1965.

276 However, individuals who died were more likely to have not mounted a cellular res

277 Patients who died were older (mean [SD] age, 68.7 [14.8] years vs 60.

278 Nonresponders were those who either died, were hospitalized for HF, or had <5-point improvem

279 ive cells were more likely to arrest than to die, whereas slowly proliferating cells showed a higher

280 Thirteen participants died while in the trial (intervention group: 9; control

281 More patients died with 2 complication versus 1 complication vs no com

282 atic activities in the brains of persons who died with AD suggest that this reduction is the main cau

283 r patients had [(18) F]-flortaucipir-PET and died with FTLD (progressive supranuclear palsy [PSP], n

284 One subject in the investigational arm died with functioning pancreas and kidney grafts.

285 ough a recent autopsy series of patients who died with severe COVID-19 in China found acute tubular n

286 Thirty-three percent of patients have died, with significant geographic variability, ranging f

287 A total of 38 302 (19.4%) died within 1 year of discharge, including 7.3% of patie

288 Of 18 102 patients discharged, 3461 (20%) died within 1 year.

289 Of the 389 enrolled patients, 133 (34.2%) died within 180 days of ICU admission.

290 Patients who died within 3 days of peak troponin concentration withou

291 Two enrolled patients died within 3 months of treatment from pre-existing como

292 Two patients (4.3%) died within 30 days due to sepsis and gastroduodenal art

293 In the ACEI/ARB group, 18.1% died within 30 days vs 7.3% in the nonuser group, but th

294 215 (10%) of all women had died within 6 months of diagnosis, but 3-year overall su

295 In the standard TTS arm 5 patients (4.3%) died within 90 days of surgery, compared to 4 patients (

296 omogram score, approximately 50% of patients died within a year of resection.

297 Interestingly, patients dying within 3 months on the waiting list displayed elev

298 bated, of whom 66 subsequently died, and 166 died without intubation).

299 Fewer young mothers have experienced a child die, yet in many countries, up to one-third have.

300 lso across both cohorts, cases with FTLD-TDP died younger than those with LATE-NC (P < 0.0001).